Literature DB >> 19489685

The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.

Ettore Mearini1, Cinzia Antognelli, Chiara Del Buono, Giovanni Cochetti, Antonella Giannantoni, Emanuela Nardelli, Vincenzo N Talesa.   

Abstract

The identification of reliable molecular biomarkers in prostate cancer early diagnosis is clinically desirable. We quantitatively detected prostate cancer specifically overexpressed genes, DD3 and PSA, in urine sediments of men suffering from prostate cancer or benign prostate hyperplasia, after prostatic massage. As both genes are exclusively expressed in androgen receptor expressing human prostate carcinoma cell lines, we further investigated the possible effect of androgens on PSA and DD3 gene expression. DD3 and PSA mRNA levels were measured by real-time polymerase chain reaction. The combined markers test had a sensitivity of 80.2% and a specificity of 100%. Both gene transcripts were significantly upregulated by androgens. Results indicated the clinical usefulness of the combination of DD3 and PSA as molecular markers in the early diagnosis of prostate cancer and the need of combining as many as possible analytical data with the clinical and demographic ones to achieve the maximum level of diagnostic accuracy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19489685     DOI: 10.1080/13547500902807306

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  11 in total

Review 1.  PCA3 in the detection and management of early prostate cancer.

Authors:  Xavier Filella; Laura Foj; Montserrat Milà; Josep M Augé; Rafael Molina; Wladimiro Jiménez
Journal:  Tumour Biol       Date:  2013-03-16

Review 2.  Diagnosis of prostate cancer via nanotechnological approach.

Authors:  Benedict J Kang; Minhong Jeun; Gun Hyuk Jang; Sang Hoon Song; In Gab Jeong; Choung-Soo Kim; Peter C Searson; Kwan Hyi Lee
Journal:  Int J Nanomedicine       Date:  2015-10-19

Review 3.  Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.

Authors:  Yong Cui; Wenzhou Cao; Quan Li; Hua Shen; Chao Liu; Junpeng Deng; Jiangfeng Xu; Qiang Shao
Journal:  Sci Rep       Date:  2016-05-10       Impact factor: 4.379

4.  Evaluation of Combined Quantification of PCA3 and AMACR Gene Expression for Molecular Diagnosis of Prostate Cancer in Moroccan Patients by RT-qPCR

Authors:  Imane Abdellaoui Maane; Hicham El Hadi; Zineb Qmichou; Abderrahmane Al Bouzidi; Youssef Bakri; Hassan Sefrioui; Nadia Dakka; Abdeladim Moumen
Journal:  Asian Pac J Cancer Prev       Date:  2016-12-01

5.  The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer.

Authors:  Ana Emília Goulart Lemos; Aline da Rocha Matos; Luciana Bueno Ferreira; Etel Rodrigues Pereira Gimba
Journal:  Oncotarget       Date:  2019-11-12

6.  Identification of Urinary Exosomal miRNAs for the Non-Invasive Diagnosis of Prostate Cancer.

Authors:  Zhuo Li; La-Xiu Li; Yan-Jun Diao; Juan Wang; Yun Ye; Xiao-Ke Hao
Journal:  Cancer Manag Res       Date:  2021-01-06       Impact factor: 3.989

7.  PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling.

Authors:  Luciana Bueno Ferreira; Antonio Palumbo; Kivvi Duarte de Mello; Cinthya Sternberg; Mauricio S Caetano; Felipe Leite de Oliveira; Adriana Freitas Neves; Luiz Eurico Nasciutti; Luiz Ricardo Goulart; Etel Rodrigues Pereira Gimba
Journal:  BMC Cancer       Date:  2012-11-06       Impact factor: 4.430

8.  Glyoxalase 1-419C>A variant is associated with oxidative stress: implications in prostate cancer progression.

Authors:  Cinzia Antognelli; Letizia Mezzasoma; Ettore Mearini; Vincenzo Nicola Talesa
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

Review 9.  Glyoxalases in Urological Malignancies.

Authors:  Cinzia Antognelli; Vincenzo Nicola Talesa
Journal:  Int J Mol Sci       Date:  2018-01-31       Impact factor: 5.923

10.  Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis.

Authors:  Zhiqiang Qin; Jianxiang Yao; Luwei Xu; Zheng Xu; Yuzheng Ge; Liuhua Zhou; Feng Zhao; Ruipeng Jia
Journal:  Int Braz J Urol       Date:  2020 Sep-Oct       Impact factor: 3.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.